MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
stock, net of issuance...
$6,919,432
Net cash provided by
financing activities
$6,919,432
Net increase
(decrease) in cash and cash...
$4,203,545
Canceled cashflow
$2,715,887
Accounts payable and
accrued expenses
$2,261,456
Amortization of deferred
offering cost
$496,948
Stock-based compensation
expense
$419,245
Common stock issued in
exchange for services
$250,000
Prepaid expenses and
other current assets
-$105,025
Depreciation and
amortization
$52,746
Non-cash operating lease
expense
$1,172
Net cash used in
operating activities
-$2,562,901
Net cash used in
investing activities
-$152,986
Canceled cashflow
$3,586,592
Net loss
attributable to common...
-$3,194,080
Purchases of intangible
assets
$152,986
Net gain from change
in fair value of...
$2,574,971
Gain from change in
fair value of forward...
-$380,442
Back
Back
Cash Flow
source: myfinsight.com
Turn Therapeutics Inc. (TTRX)
Turn Therapeutics Inc. (TTRX)